In NSCLC, the CCDC6 involvement can be ascribed both to the low levels of the protein expression, as reported in 30% of patients, and correlated with tumor progression and bad prognosis (OS and DFS) [16], and to the fusion of the first CCDC6 101 aa with the RET and ROS1 kinases, as detected in about 1% of NSCLC patients. The gene discussed is CCDC6; the disease is neoplasm.